Oncolytics Biotech Stock
Oncolytics Biotech Stock
Pros and Cons of Oncolytics Biotech in the next few years
Pros
Cons
Performance of Oncolytics Biotech vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Oncolytics Biotech | - | - | - | - | - | - | - |
| Resverlogix Corp | -2.000% | 9.701% | 32.432% | 122.727% | 172.222% | -39.256% | -86.875% |
| Enwave Corporation | 0.000% | 3.810% | 3.810% | 67.692% | 57.971% | -29.677% | -71.835% |
| Aurinia Pharmaceuticals Inc. | -0.650% | -4.180% | 6.640% | 61.566% | 53.538% | 176.695% | 9.113% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Oncolytics Bio, operating under the US symbol ONCY, is a company in the Biotechnology & Medical Research industry. At a glance, the financial statements of the company indicate a mixture of promising and challenging aspects. While the company seems to have a burgeoning investment and growing stockholders' equity, it is also experiencing increasing expenses and a net loss across recent years.
In 2021, the company's total assets grew notably, reaching CAD 45,880,191 from CAD 34,345,567 in 2020. This growth indicates that the company is increasing its resources and capabilities.
The cash balance increased significantly from USD 14,148,021 in 2020 to CAD 41,262,044 in 2021 and then dropped to CAD 15,872,000 in Q1 2023. However, this still indicates a positive growth in the company's cash position over the long term, which can be used for future investments and other business operations.
Comments